Chicago, IL, July 5, 2026 To: Biochemical Pharmacology Editorial Office Pharmacological Restoration of NAD+ Homeostasis Protects against Cholesterol-Induced Hepatotoxicity by Reactivating the PARP1-AMPK Axis

Authors:

Abstract
Excess hepatic cholesterol contributes to the progression of metabolic liver diseases, including both metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), yet the mechanisms by which cholesterol disrupts hepatocellular metabolic homeostasis and promotes liver injury remain poorly understood. Here, we investigated whether disruption of hepatic NAD⁺ homeostasis contributes to cholesterol-induced hepatotoxicity and evaluated the underlying molecular mechanisms and therapeutic potential of restoring NAD+ metabolism. Using cholesterol-loading models in cultured hepatocytes and mice, we found that cholesterol markedly disrupted hepatic NAD+ homeostasis by suppressing nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. Pharmacological restoration of NAD+ homeostasis with nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide N-methyltransferase (NNMT) inhibitors, or preservation of protein PARylation through PARG inhibition effectively attenuated cholesterol-induced hepatocyte injury, restored PARP1 activity, and reactivated AMPK signaling both in vitro and in vivo. Mechanistically, cholesterol suppressed O-GlcNAc transferase (OGT) expression and protein O-GlcNAcylation, leading to SP1 inactivation, transcriptional repression of Nampt, disruption of NAD+ homeostasis, and subsequent inhibition of the PARP1-AMPK signaling axis. We further identified PARP1 as a positive regulator of AMPK via PARPylation, thereby linking impaired NAD+ homeostasis to defective adaptation to metabolic stress. In contrast to saturated fatty acid-induced lipotoxicity, cholesterol-induced hepatotoxicity occurred independently of SIRT1 and mTORC1 signaling, indicating a distinct pathogenic mechanism. Collectively, these findings identify the OGT-SP1-NAMPT-NAD+-PARP1-AMPK axis as a previously unrecognized mechanism underlying cholesterol-induced hepatotoxicity and demonstrate that pharmacological restoration of NAD+ homeostasis represents a promising therapeutic strategy for cholesterol-associated liver diseases.